Evidence map›Paper›PMID 41491306›Full record

ArticleScientific reports2026

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen.

Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Seigo Yoneyama, Yumi Kotoda, Daphne Viel Tsuru, Kenji Kashiwagi

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wataru KikushimaDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3898, Japan.
Yoichi SakuradaDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3898, Japan. sakurada@yamanashi.ac.jp.
Yoshiko FukudaDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3898, Japan.
Seigo YoneyamaDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3898, Japan.
Yumi KotodaDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3898, Japan.
Daphne Viel TsuruDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3898, Japan.
Kenji KashiwagiDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3898, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We compared 12-month treatment outcomes of intravitreal injections of brolucizumab (IVBr) with aflibercept (IVA) for treatment-naïve exudative age-related macular degeneration (AMD). Patients were given three monthly IVBr or IVA injections and were followed up monthly for 12 months. Additional injections were given if exudation or hemorrhage recurred. The study included 339 eyes in 339 patients divided into the IVBr or IVA groups. In both groups, central retinal thickness (CRT) and subfoveal choroidal thickness significantly decreased, and best-corrected visual acuity (BCVA) significantly improved at the 12-month visit. BCVA improvement was similar in both groups (P = 0.27). Age, baseline BCVA, and thickness of the central retina and subfoveal choroid were associated with the 12-month BCVA. The proportion of patients who did not require additional injections was 33% in the IVBr and 30% in the IVA group (P = 0.58). The number of additional injections showed a trend favoring IVBr over IVA but the difference was insignificant (P = 0.055). Age, risk alleles of ARMS2 A69S, and baseline CRT were associated with shorter retreatment-free period. In conclusion, IVBr achieved similar visual and anatomic treatment outcomes to IVA with a trend toward requiring fewer additional injections during 12-month follow-up of as-needed regimen for exudative AMD.

Indexed as

Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedMacular DegenerationReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAgedAged, 80 and overFemaleHumansIntravitreal InjectionsMaleTreatment OutcomeVisual AcuityafliberceptAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedbrolucizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAfliberceptAge-related macular degenerationBrolucizumabPolypoidal choroidal vasculopathyRecurrence

Identifiers

PMID41491306
PMCPMC12873363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.